Veraxa Biotech Holding AG focus on antibody therapies in medicine. The Company is an oncology-focused biotechnology Company with a clinical program in acute myeloid leukemia and two proprietary platform technologies that enable the development of new generations of antibody drug conjugates (ADC's) and T cell engagers. The Company operates in one reportable segment, focused on the research and development of products for the aging population.
Last trade$1.03
Day change-$0.015 (-1.44%)
Day range$1.03 – $1.07
Volume73,634
Market cap$148M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for VRXA.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for VRXA.
Recent news
Company coverage with links to the original publishers.
VERAXA Biotech announced its implementation of FDA-aligned New Approach Methodologies (NAMs) across its preclinical R&D programs to accelerate its BiTAC oncology pipeline while significantly reducing animal testing. The company presented data showing its BiTAC-TCE candidates demonstrated superior safety profiles and matched efficacy compared to traditional T cell engagers, with ex vivo studies using patient-derived xenograft models requiring only 10 mice versus 200+ for traditional studies.
VERAXA Biotech AG announced the appointment of Raju Willener as Chief Financial Officer, effective immediately. Willener brings over 30 years of experience in global capital markets and biopharmaceutical finance. The appointment comes as VERAXA advances its BiTAC® platform and oncology pipeline toward clinical development.
VERAXA Biotech announced substantial progress in its pipeline and partnering strategy, with plans to focus investments on its BiTAC platform for T cell engagers and antibody-drug conjugates. The company aims to have its lead BiTAC-TCE candidate VXA-102 IND/CTA-ready by early 2028 and intends to monetize non-BiTAC assets to finance growth. The company is actively pursuing partnerships and reported strong industry interest in its novel BiTAC technology.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.